You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Pre-index patient characteristics

From: Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis

Variable Combined population Medicaid population Commercial population
Lurasidone Quetiapine Lurasidone Quetiapine Lurasidone Quetiapine
n = 238 n = 435 n = 122 n = 215 n = 116 n = 220
Demographics
Age, (Mean, SD) 37.1 13.4 37.6 14.2 39.1 12.8 38.2 12.9 34.9 13.8 36.9 15.3
Female (N, %) 145 61 225* 52 82 67 129 60 63 54 96 44
Comorbidities, (N, %)
 Psychiatric
  Alcohol/Substance Abuse 53 22 159* 37 41 34 84 39 12 10 75* 34
  Anxiety 67 28 170* 39 39 32 84 39 28 24 86* 39
  Bipolar Disorder 108 45 231 53 57 47 106 49 51 44 125* 57
  Depression 99 42 225* 52 51 42 117* 54 48 41 108 49
  Personality Disorders 25 11 45 10 18 15 28 13 7 6 17 8
Cardiometabolic
  Diabetes 41 17 61 14 25 21 39 18 16 14 22 10
  Hyperlipidemia 48 20 93 21 30 25 52 24 18 16 41 19
  Hypertension 69 29 144 33 49 40 88 41 20 17 56 25
Medications, (N, %)
 Psychiatric
  Antidepressants 177 74 313 72 98 80 169 79 79 68 144 66
  Anxiety 65 27 172* 40 27 22 78* 36 38 33 94 43
  Hypnotics 80 34 142 33 53 43 84 39 27 23 58 26
  Mood stabilizers 130 55 269 62 67 55 130 61 63 54 139 6
  Stimulants 21 9 22 5 1 1 3 1 20 17 19* 9
  Typical antipsychotics 23 10 63 15 12 10 29 14 11 10 34 15
 Other
  Antidiabetics 38 16 50 12 22 18 30 14 16 14 20 9
  Antihypertensives 62 26 124 29 43 35. 72 33 19 16 52 24
  Antilipidemic 55 23 76 18 36 29 40* 19 19 16 36 16
 Switch from atypical antipsychotic
  Aripiprazole 58 24 90 21 26 21 41 19 32 28 49 22
  Asenapine 24 10 10* 2 12 10 4* 2 12 10 6* 3
  Clozapine 4 2 6 1 2 2 3 1 2 2 3 1
  Iloperidone 10 4 13 3 5 4 5 2 5 4 8 4
  Paliperidone 43 18 74 17 18 15 30 14 25 22 44 20
  Olanzapine 28 12 18* 4 17 14 11* 5 11 10 7* 3
  Risperidone 56 24 159* 37 27 22 81* 38 29 25 78 35
  Ziprasidone 38 16 89 20 23 19 53 25 15 13 36 16
Inpatient admissions, (N, %)             
All-cause 98 41 274* 63 44 36 114* 53 54 47 160* 73
Mental health-related 98 41 272* 63 44 36 113* 53 54 47 159* 72
Schizophrenia-related 80 34 214* 4* 34 28 95* 44 46 40 119* 54
Total cost, (Mean, SD)a      13,883 16,721 15,008 14,086 15,379 17,352 23,061* 30,804
  1. aExpenditures for the combined Medicaid/Commercial population are not reported due to different payment structures
  2. *p < 0.05; Statistically significantly different from lurasidone cohort